COMMUNIQUÉS West-GlobeNewswire

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)
13/05/2025
COPENHAGEN, Denmark, May 13, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 of its pivotal ApproaCH Trial of [...]
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
13/05/2025
Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus Erythematosus to be Featured in Oral Presentation at EULAR 2025 Congress in June Regenerative Medicine [...]
Glass House Brands Reports First Quarter 2025 Financial Results
13/05/2025
Wholesale biomass production was 152,568 pounds, up 149% year-over-year Cost of production was $108 per pound, a substantial improvement compared to $182 per pound in Q1 2024 First quarter 2025 revenue was $44.8 million [...]
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
13/05/2025
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced [...]
NeuroPace Reports First Quarter 2025 Financial Results
13/05/2025
-- Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products -- -- Increased full-year 2025 revenue guidance to $93 to $97 million -- -- On track to [...]
Iridex Reports First Quarter 2025 Financial Results
13/05/2025
MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for [...]
Spectral AI Announces 2025 First Quarter Financial Results
13/05/2025
Q1 Overview Research & Development Revenue of $6.7 Million Improved Capital Structure Reflected in Cash of $14.1 Million Continued work on planned De Novo submission to the FDA in the first half of 2025 DALLAS, May [...]
Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
13/05/2025
Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under priority review by the U.S. FDA, with a target Prescription Drug User Fee Act (PDUFA) date slated [...]
Zevra Reports First Quarter 2025 Financial Results and Corporate Update
13/05/2025
Q1 2025 net revenue of $20.4 million, driven by product net revenue of $17.2 million Completed sale of PRV for gross proceeds of $150 million, positioning balance sheet to drive the Company ’ s commercial launches and [...]
NEXGEL Reports First Quarter 2025 Financial Results
13/05/2025
First quarter 2025 revenue totaled $2.81 million, an increase of 121%, as compared to $1.27 million for the same period the prior year Gross Profit for the quarter was 42.4%, compared to 12.6% in Q1 2024 and 37.2% in Q4 [...]
Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update
13/05/2025
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Nearly 50 Sites Activated Across U.S. with Strong Enthusiasm from Investigators [...]
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
13/05/2025
– Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarter, the most in company history and a 16.7% growth over Q4’24 [...]
Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates
13/05/2025
REVEAL-1 Cohort 3-month open-label data update expected in June 2025; early clinical signals reinforce Revita’s potential to maintain weight loss after GLP-1 discontinuation in the real world REMAIN-1 Midpoint Cohort [...]
Hyperfine, Inc. Reports First Quarter 2025 Financial Results
13/05/2025
GUILFORD, Conn., May 13, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic [...]
Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results
13/05/2025
Actively screening for the 10,000 participant portion of COVID-19 Phase 2b trial; Dosing expected to begin in second quarter of 2025 Completed enrollment of Phase 1 clinical trial evaluating Company’s second-generation [...]
MannKind to Present at Upcoming Investor Conferences
13/05/2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative inhaled therapeutic products [...]
Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates
13/05/2025
Interim analysis focused on disease-free survival (“DFS”) in randomized Phase 2 AMPLIFY-7P clinical trial expected in Q3 2025 Company has alignment with U.S. Food and Drug Administration (“FDA”) on key design elements [...]
Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
13/05/2025
sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation to [...]
Erasca Reports First Quarter 2025 Business Updates and Financial Results
13/05/2025
Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet [...]

Pages